

## PRELIMINARY PROGRAM



# 46<sup>th</sup> Annual Meeting of the European Thyroid Association

[www.eta2024.com](http://www.eta2024.com)



**7-10** September  
2024  
Athens Conservatoire  
Greece

**Saturday, 7. September 2024**

---

## **PRE - Courses**

### **Scientific and Clinical UPDATE**

*(Registration required, subject to charge)*

**Aris Garoufalidis Auditorium**

**08:00 - 13:00 h**      **ETA Cancer Group**

**New Stage 2**

**08:00 - 13:00 h**      **Iodine Global Network (IGN)**

**New Stage 1**

**08:45 - 12:45 h**      **ETA Basic Update**

**Amphitheatre**

**09:00 - 13:00 h**      **ETA Clinical Update**

**Ω2 Complex**

**09:00 - 12:45 h**      **ETA Ultrasound Course**

---

Saturday, 7. September 2024

## 46th Annual Meeting of the ETA

### Scientific Program

**Amphitheatre**

**13:30 - 13:50 h**

**Opening Ceremony**

*Chair(s): Leonidas Duntas (Greece) and Laura Fugazzola (Italy)*

**Amphitheatre**

**13:50 - 15:20 h**

**Oral Session 1: Topic Highlights**

*Chair(s): Leonidas Duntas (Greece) and Laura Fugazzola (Italy)*

13:50 - 14:00

Birth defects in children born to mothers with thyroid disease: biochemical assessment in 20,399 pregnancies substantiates that thyroid function and thyroid autoimmunity are not the causal links  
*Stine Linding Andersen (Denmark)*

14:05 - 14:15

Reprogramming myeloid bone marrow progenitors in non-medullary thyroid cancer using trained immunity  
*Pepijn van Houten (Netherlands)*

14:20 - 14:30

Novel TR- $\beta$  selective Agonist TG68 promotes anti-inflammatory, lipid-lowering and anxiolytic effects  
*Beatrice Polini (Italy)*

14:35 - 14:45

Unveiling Severe Adverse Events of Antithyroid Drugs in Patients with Graves' disease; A Real-World Multicenter Cohort Study  
*Soo Myoung Shin (Korea, Rep. of South)*

14:50 - 15:00

Dabrafenib and trametinib in BRAFV600E anaplastic thyroid cancers: an Italian real-word series  
*Rossella Elisei (Italy)*

15:05 - 15:15

CUT&Tag reveals distinct TR $\alpha$ 2-specific DNA binding profiles in hiPSC-derived cardiomyocytes  
*Nina Härting (Germany)*

**Saturday, 7. September 2024**

**Ω2 / Poster Hall**

**16:35 – 17:35 h**      **Poster Session 1**

**Amphitheatre**

**17:40 - 19:10 h**      **Symposium 1 (clinical): Indeterminate nodules**

*Chair(s): Birte Nygaard (Denmark)*

17:40 - 18:05      New edition Bethesda system for reporting thyroid cytopathology  
*Laetitia Lebrun (Belgium)*

18:10 - 18:35      Any role for further imaging  
*Steen Bonnema (Denmark)*

18:40 - 19:05      Surveillance  
*Enrico Papini (Italy)*

**Aris Garoufalidis Auditorium**

**17:40 - 19:10 h**      **Symposium 2: (basic cancer)**  
**Advanced thyroid cancer: beyond driver mutations**

*Chair(s): Paula Soares (Portugal)*

17:40 - 18:05      Epigenetics in thyroid cancer  
*Mireia Jorda (Spain)*

18:10 - 18:35      Cell Autonomous and Microenvironment-driven Mechanisms of Thyroid Tumor  
Resistance to Targeted Therapies  
*Carmelo Nucera (United States)*

18:40 - 19:05      Neoantigen landscape and immune microenvironment of oncocytic carcinoma  
*Ian Ganly (United States)*

**New Stage 1**

**17:40 - 18:25 h**      **Meet the Expert 1:**  
Microbiome research in Graves Disease and Graves orbitopathy  
*Marian Ludgate (United Kingdom)*

**New Stage 1**

**18:25 - 19:10 h**      **Meet the Expert 2:**  
Writing a successful basic research grant  
*Christopher McCabe (United Kingdom)*

**Amphitheatre**

**19:15 - 19:45 h**      **ETJ Lecture**  
*Chair: Luca Persani (Italy)*

**Sunday, 8. September 2024**

**Amphitheatre**

- 08:00 - 09:30 h**      **Symposium 3: (clinical)**  
**The knows and unknowns of medical treatments for Graves' Orbitopathy**  
*Chair(s): Tomasz Bednarczyk (Poland)*
- 08:00 - 08:25      anti-IL therapies  
*Milos Zarkovic (Serbia)*
- 08:30 - 08:55      m-TOR inhibitors and statines  
*Michele Marino (Italy)*
- 09:00 - 09:25      IgF –1 antagonists  
*George Kahaly (Germany)*

**Aris Garoufalidis Auditorium**

- 08:00 - 09:30 h**      **Symposium 4: (basic)**  
**Role of thyroid hormone in liver development and metabolism**  
*Chair(s): Eveline Bruinstroop (Netherlands)*
- 08:00 - 08:25      Role of THR-beta controlling hepatocyte identity  
*Jerôme Eeckhoutte (France)*
- 08:30 - 08:55      THR signalling in liver  
*Lars Christian Möller (Germany)*
- 09:00 - 09:25      Thyroid hormone action in iPSCs derived hepatocytes  
*Anthony Hollenberg (United States)*

**Amphitheatre**

- 10:00 - 10:45 h**      **Meet the Expert 3:**  
20 years of BRAF and thyroid cancer: all you need to know about the most frequent genetic alteration  
*Miguel Melo (Portugal)*

**Aris Garoufalidis Auditorium**

- 10:00 - 10:45 h**      **Meet the Expert 4:**  
ETA GL on interference with TFT  
*David Halsall (United Kingdom)*

**Sunday, 8. September 2024**

**New Stage 1**

**10:00 - 11:00 h**      **Oral Session 2: TH action in the brain**

*Chair(s):*

10:00 - 10:10      Thyroid hormone transporters Mct8 and Oatp1c1 exhibit cell-autonomous functions within the oligodendroglia cell lineage in the mouse CNS  
*Joshua-Joel Richter (Germany)*

10:12 - 10:22      Gestational hypothyroxinemia in Dehal1KO mice: discordant T3-dependent gene expression in brain regions and autistic-like phenotype in the offspring.  
*Pouya Alikhani (Spain)*

10:24 - 10:34      Thyroid hormone transporters Mct8 and Oatp1c1 are required for proper angiogenesis in the mouse CNS  
*Androniki Alevyzaki (Germany)*

10:36 - 10:46      Exploring the role of TR $\beta$  in the process of cortical neuron differentiation  
*Giuditta Rurale (Italy)*

10:48 - 10:58      A novel Mct8 point-mutant mouse model shows effectiveness of phenylbutyrate treatment  
*Doreen Braun (Germany)*

**Aris Garoufalidis Auditorium**

**10:55 - 11:40 h**      **Meet the Expert 5:**  
Mouse models of thyroid cancer  
*Iñigo Landa (United States)*

**$\Omega$ 2 / Poster Hall**

**12:20 - 13:20**      **Poster Session 2**

**Sunday, 8. September 2024**

**Amphitheatre**

- 13:30 - 15:30 h**      **Oral Session 3: Young Investigator / Clinical + Translational**  
*Chair(s):*
- 13:30 - 13:45      Impact of Reclassification of Oncocytic and Follicular Thyroid Carcinoma by the 2022 WHO Classification  
*Merel Stegenga (Netherlands)*
- 13:50 - 14:05      Impact of physical activity and its maintenance in the efficacy and safety of tyrosine kinase inhibitors in advanced thyroid carcinoma patients  
*Daniele Ceruti (Italy)*
- 14:10 - 14:25      Effects of tocilizumab treatment in corticosteroid-resistant Graves' orbitopathy.  
*Joanna Rymuza (Poland)*
- 14:30 - 14:45      T3 analogue Triiodothyroacetic acid (Triac) treatment and survival in MCT8 deficiency: an international real-world cohort study  
*Floor van der Most (Netherlands)*
- 14:50 - 15:05      Predictors of disease progression in patients with suspicious lymph nodes after initial treatment for thyroid carcinoma  
*Matteo Trevisan (Italy)*
- 15:10 - 15:25      The association of maternal thyroid function with offspring IQ and brain morphology: persistency into early adolescence and relevance of TPOAb positivity  
*Joris Osinga (Netherlands)*

**Aris Garoufalidis Auditorium**

- 13:30 - 15:30 h**      **Oral Session 4: Young Investigator / Basic**  
*Chair(s):*
- 13:30 - 13:45      Identifying novel DIO1 inhibitors to modulate hepatic T3 availability in context of non-alcoholic fatty liver disease  
*Rajas Sane (Germany)*
- 13:50 - 14:05      Thyroid hormone transporters Mct8/Oatp1c1 deficient mice exhibit increased seizure susceptibility together with an imbalanced hippocampal neurotransmission  
*Andrea Alcaide Martin (Germany)*
- 14:10 - 14:25      The role of type 3 Deiodinase in a human model for early brain development  
*Anna López Martí (Netherlands)*
- 14:30 - 14:45      Blood-brain barrier leakage and neurovascular unit ultrastructural alterations as new pathophysiological mechanisms for MCT8 Deficiency  
*Marina Guillén Yunta (Spain)*
- 14:50 - 15:05      Investigating the role of Dicer1 in thyroid tumorigenesis  
*Maria Rojo (Belgium)*
- 15:10 - 15:25      Single cell analysis of a thyroid cancer cell line resistant to Lenvatinib  
*Helena Rodríguez-Lloveras (Spain)*

**Sunday, 8. September 2024**

**Aris Garoufalidis Auditorium**

**15:45 - 16:30 h**

**Meet the Expert 6:**

Studying the role of thyroid hormone in sensory organs  
*Douglas Forrest (United States)*

**Amphitheatre**

**17:10 - 18:40 h**

**Symposium 5: (clinical)  
Thyroid and Pregnancy**

Chair(s): *Kris Poppe (Belgium)*

17:10 - 17:35

Overt hypothyroidism during pregnancy; always treat ! But what is the evidence?  
*Alicja Hubalewska-Dydejczyk (Poland)*

17:40 - 18:05

LT4 is not the answer for euthyroid pregnant women with TAI, but what is?  
*Gesthimani Mintziori (Greece)*

18:10 - 18:35

Suppressed TSH during early pregnancy (not) always innocent?  
*Tim Korevaar (Netherlands)*

**Aris Garoufalidis Auditorium**

**17:10 - 18:40 h**

**Symposium 6: (basic)  
Basic hypothyroidism**

Chair(s): *Steffen Mayerl (Germany)*

17:10 - 17:35

Genetic determinants of thyroid hormone setpoint - a worldwide GWAS study  
*Marco Medici (Netherlands)*

17:40 - 18:05

Iodotyrosines predict iodine-deficient hypothyroidism in Dehal1KO mice  
*Jose Moreno (Spain)*

18:10 - 18:35

Transplantable human thyroid organoids to rescue hypothyroidism  
*Sabine Costagliola (Belgium)*

**Amphitheatre**

**18:45 - 19:05 h**

**ETA Lissitzky award**

Chair(s): *Laura Fugazzola (Italy) and Kris Poppe (Belgium)*



**Monday, 9. September 2024**

**Amphitheatre**

**08:00 - 09:30 h**      **Symposium 7: (translational)**  
**Novel aspects in thyroid hormone actio**  
Chair(s):            ()

08:00 - 08:25      New insights on T3 signalling  
*Balazs Gereben (Hungary)*

08:30 - 08:55      Novel aspects of tissue regulation of thyroid hormone action  
*Ana Guadaño-Ferraz (Spain)*

09:00 - 09:25      Emerging aspects of THR-alpha action  
*Riccardo Dore (Germany)*

**Aris Garoufalidis Auditorium**

**08:00 - 09:30 h**      **Oral Session 5: Thyroid dysfunction-1**  
Chair(s):            ()

08:00 - 08:10      A Novel Point of Care Device Accurately and Rapidly Measures Thyrotropin in  
Capillary Blood  
*George Kahaly (Germany)*

08:12 - 08:22      Exploring the Relationship Between TSH Levels and Cardiovascular Health in  
Euthyroid Individuals: Insights from ELSA-Brasil Study.  
*Henrique Luca Lucchesi (Brazil)*

08:24 - 08:34      Cardiovascular risk and mortality in a large Italian cohort of patients with resistance  
to thyroid hormone  $\beta$  (RTH $\beta$ ).  
*Irene Campi (Italy)*

08:36 - 08:46      The quality of life impact of weight gain in treated hyperthyroidism  
*Angelos Kyriacou (Cyprus)*

08:48 - 08:58      Effect of the T3 analogue Triac on patient-centered outcome measures in patients  
with MCT8 deficiency: post-hoc analysis of the international Triac Trial I.  
*Matthijs Freund (Netherlands)*

09:00 - 09:10      Systematic review of mortality and long-term major cardiovascular events (MACE)  
following different treatment approaches for hyperthyroidism.  
*Lauren Quinn (United Kingdom)*

09:12 - 09:22      Long-term outcomes of LT4/LT3 combination treatment for persistent hypothyroid  
symptoms  
*Birte Nygaard (Denmark)*

**Monday, 9. September 2024**

**New Stage 1**

**08:00 - 09:30 h**

**Oral Session 6: Translational thyroid cancer research**

Chair(s): ()

08:00 - 08:10

The Role of TPO Antibodies in Immune Escape of Aggressive Tumors of Thyroid Follicular Cells.

*Rodis Paparodis (Greece)*

08:12 - 08:22

Clinical Utility Of Circulating Tumoral DNA Analysis By Multi-Gene NGS Panels In Therapy Monitoring Of Advanced Sporadic Medullary Thyroid Carcinoma Patients

*Raffaele Ciampi (Italy)*

08:24 - 08:34

Digoxin treatment does not reinduce uptake of radioiodine in metastatic radioiodine refractory non-medullary thyroid carcinoma

*Pepijn van Houten (Netherlands)*

08:36 - 08:46

Clinically relevant germline genetic variants and somatic fusions underlying paediatric thyroid cancer risk and aggressiveness

*Carolina Pires (Portugal)*

08:48 - 08:58

Molecular profiling of low-risk papillary thyroid carcinomas (mPTC) on active surveillance

*Arianna Ghirri (Italy)*

09:00 - 09:10

Clinical implications of the gut microbiome in anaplastic thyroid cancer

*Anastasios Maniakas (United States)*

09:12 - 09:22

Performance of the mir-THYpe new version algorithm in classification of Thyroid Indeterminate Nodules: Latin American Multicenter Validation Study

*Marcos Santos (Brazil)*

**Amphitheatre**

**10:00 - 10:45 h**

**Meet the Expert 7:**

Minimal Invasive Techniques

*Giovanni Mauri (Italy)*

**Monday, 9. September 2024**

**Aris Garoufalidis Auditorium**

**10:00 - 11:00 h Oral Session 7: TH mechanisms in diseases**

Chair(s): ()

- 10:00 - 10:10 The Protective role of Androgen on Experimental Graves'Hyperthyroidism in BALB/c Mice  
*Liping Wu (China)*
- 10:12 - 10:22 Abrogation of hepatic TR $\beta$  action attenuates acetaminophen-induced acute liver injury in mice  
*Manuela Kowalczyk (Germany)*
- 10:24 - 10:34 Characteristics of hyaluronan metabolism during myofibroblast differentiation in orbital fibroblasts  
*Fruzsina Réka Papp (Hungary)*
- 10:36 - 10:46 Absence of cholesterol gallstone formation in male C57BL/6 mice by abrogation of hepatic thyroid hormone action  
*Elena Schmalzer (Germany)*
- 10:48 - 10:58 Altered Skull and Bone Morphology in Hyperthyroid Knock-in Mice with TSHR M453T and D633H Mutations  
*Kristiina Makkonen (Finland)*

**New Stage 1**

**10:00 - 11:00 h Oral Session 8: Pregnancy**

Chair(s): ()

- 10:00 - 10:10 Detailed morphological phenotyping of maternal thyroid function and offspring brain development: a vertex-wise approach including assessment of gyrification  
*Tessa Mulder (Netherlands)*
- 10:12 - 10:22 Clinically relevant differences between routinely used immunoassays for thyroid function testing: A Danish study of non-pregnant and pregnant adults  
*Ida Marie Nørum Wigh (Denmark)*
- 10:24 - 10:34 Stimulating TSH-receptor antibodies in early pregnancy using the Turbo TSI bioassay: a study of 3,028 pregnant women in the North Denmark Region  
*Nanna Maria Uldall Torp (Denmark)*
- 10:36 - 10:46 Fluid intelligence evaluation through Raven's Progressive Matrices in adult patients with congenital hypothyroidism detected by neonatal screening.  
*Luisa Pignata (Italy)*
- 10:48 - 10:58 Maternal thyroid function and biochemical markers of placental function in early pregnancy  
*Maja Lundgaard (Denmark)*

Monday, 9. September 2024

Ω2 / Poster Hall

12:20 - 13:20 h **Poster Session 3**

Amphitheatre

13:30 - 14:15 h

**Meet the Expert 8:**

The role of diet in autoimmunity diseases: Real or Fake news?

*Helena Filipsson Nyström (Sweden)*

Aris Garoufalidis Auditorium

13:30 - 14:30 h

**Oral Session 9: Basic thyroid cancer research**

Chair(s): ()

13:30 - 13:40

Epigenetic deregulation and dedifferentiation in thyroid cancer

*Anna Rueda-Pujol (Spain)*

13:42 - 13:52

TP53 mutations associate with poor response to Lenvatinib treatment for advanced thyroid cancer

*Carla Colombo (Italy)*

13:54 - 14:04

Role of the oncogene UHRF1 in thyroid cancer differentiation, progression and response to Lenvatinib

*Valentina Cirello (Italy)*

14:06 - 14:16

Tumour Heterogeneity and Evolution in Advanced Thyroid Cancer through Multiregion and Longitudinal Sampling

*Leslie Cheng (United Kingdom)*

14:18 - 14:28

Tracing the molecular route to progression in defective miRNA biogenesis benign vs malignant thyroid lesions

*Anne-Sophie Chong (Spain)*

**Monday, 9. September 2024**

**New Stage 1**

- 13:30 - 14:30 h**      **Oral Session 10: Thyroid dysfunction-2**  
Chair(s):            ()
- 13:30 - 13:40      Effect of smoking status on TSH Receptor Antibody (TRAb) levels following treatment for Graves' disease  
*Sarah Matthews (United Kingdom)*
- 13:42 - 13:52      Towards personalized TSH reference ranges: A genetic and population-based approach in three independent cohorts  
*Aleksander Kuś (Poland)*
- 13:54 - 14:04      Compensatory rise in TSH when blocking sympathetic activity in cold exposed hunters in East Greenland  
*Mette Motzfeldt Jensen (Denmark)*
- 14:06 - 14:16      The relation between circulating free thyroxine (FT4) and thyroid stimulating hormone (TSH) levels is very different in people taking levothyroxine vs those who are on no thyroid hormone replacement  
*Adrian Heald (United Kingdom)*
- 14:18 - 14:28      Whole-brain computational anatomy in Graves' disease: morphometric imprint of pathology and recovery  
*Mats Holmberg (Sweden)*

**Amphitheatre**

- 16:10 - 16:55 h**      **Short Call Abstracts**  
Chair(s): *Laura Fugazzola (Italy)*

**Amphitheatre**

- 16:55 - 17:40 h**      **Pinchera Prize Lecture**  
Chair(s): *Laura Fugazzola (Italy) and Kris Poppe (Belgium)*

**Amphitheatre**

- 17:45 - 19:00 h**      **ETA General Assembly**

**Tuesday, 10. September 2024**

**Amphitheatre**

- 08:00 - 08:30 h**      **Research Grants Winner presentations 2022**  
*Chair: Kris Poppe (Belgium)*
- 08:00 - 08:10      Guanine-quadruplexes as novel players in expression and post-transcriptional regulation of THRA  
*Sebastian Hönes (Germany)*
- 08:10 - 08:20      Thyroid hormone titration for subclinical hypothyroidism in NAFLD patients  
*Eveline Bruinstroop (Netherlands)*
- 08:20 - 08:30      NN

**Amphitheatre**

- 08:30 - 09:30 h**      **A Year in ...**  
*Chair(s): Tomasz Bednarczuk (Poland)*
- 08:30 - 08:50      A Year in Clinical Thyroidology  
*Patrice Rodien (France)*
- 08:50 - 09:10      A Year in Basic Thyroidology  
*Nadia Schoenmakers (United Kingdom)*
- 09:10 - 09:30      A Year in Cancer  
*Dagmar Führer-Sakel (Germany)*

**Amphitheatre**

- 09:30 - 10:00 h**      **Historical Vignette:**  
*Chair(s): Laura Fugazzola (Italy)*
- The Anecdotal History of Screening for Congenital Hypothyroidism  
*Anita Boelen (Netherlands)*

**Tuesday, 10. September 2024**

**Amphitheatre**

- 10:45 - 12:15 h**      **Symposium 8: (cancer)**  
**Managing differentiated thyroid cancer in 2024**  
*Chair(s): Kristien Boelaert (United Kingdom)*
- 10:45 - 11:10      Role of active surveillance in DTC  
*Eleonora Molinaro (Italy)*
- 11:15 - 11:40      Which DTC require RAI ablation?  
*Livia Lamartina (France)*
- 11:45 - 12:10      When to stop follow-up?  
*Megan Haymart (United States)*

**Aris Garoufalidis Auditorium**

- 10:45 - 12:15 h**      **Oral Session 11: Molecular Thyroidology**  
*Chair(s): ()*
- 10:45 - 10:55      Thyroid hormone receptor  $\alpha 1$  is a novel regulator of p53 functions  
*Sheue-yann Cheng (United States)*
- 10:57 - 11:07      KLHL14 and its anti-sense lncRNA are involved in thyroid cells differentiation  
*Rufina Maturi (Italy)*
- 11:09 - 11:19      Molecular mechanisms of TRIAC in the treatment of resistance to thyroid hormone beta (RTH $\beta$ )  
*Marcel Meima (Netherlands)*
- 11:21 - 11:31      Systematic Screening of Natural Compounds: Impacts on Thyroid Transcriptional Activity and Nrf1/Nrf2 Activation  
*Georgios Psarias (Switzerland)*
- 11:33 - 11:43      Perinatal exposure to TBBPA interferes with the establishment of the thyroid axis at young age and the ability to cope with metabolic challenges in adulthood  
*Marie-Stéphanie Clerget-Froidevaux (France)*
- 11:45 - 11:55      Unraveling the Genetic Landscape of Hypothyroidism: Insights from a Multi-Ancestry GWAS Meta-Analysis  
*Melissa Bujnis (United States)*
- 11:57 - 12:07      Hepatocyte-specific Dio3 Knockout influences energy metabolism in female mice  
*Yingfu Chen (Germany)*

**Tuesday, 10. September 2024**

**Amphitheatre**

- 12:25 - 13:55 h**      **Oral Session 12: Clinical thyroid cancer research**  
Chair(s):            ()
- 12:25 - 12:35      Predictive factors of persistent disease in a large cohort of pediatric patients with differentiated thyroid carcinoma  
*Simone De Leo (Italy)*
- 12:37 - 12:47      Insights from Active Surveillance: Patterns of Papillary Thyroid Carcinoma Growth and Conversion Surgery Outcomes  
*Iwao SUGITANI (Japan)*
- 12:49 - 12:59      Patients with medullary thyroid carcinoma and long term treatment with vandetanib : a study from the ENDOCAN –TUTHYREF network  
*Hélène Lasolle (France)*
- 13:01 - 13:11      PRONOSThYc: prognostic factors in radioiodine refractory differentiated thyroid cancer with distant metastases, a multicentric study from a French network of referral centers  
*Alfonso Sagnella (Italy)*
- 13:13 - 13:23      Real world outcomes of patients with radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) treated in 1L with lenvatinib 24mg: An international multicenter real-world study in Europe and Canada  
*Charley Cooper (United Kingdom)*
- 13:25 - 13:35      Insight of prospective NoRA (No Radioiodine Ablation) study in patients with differentiated thyroid carcinoma (DTC)  
*Giulia Lisi (Italy)*
- 13:37 - 13:47      Randomized Clinical Trial of Prophylactic Central Neck Dissection in 2100 Papillary Thyroid Carcinoma Patients with Clinically Negative Central Neck Metastasis: An Interim Analysis of A Single Institution  
*Kyorim Back (Korea, Rep. of South)*



**Tuesday, 10. September 2024**

**Aris Garoufalidis Auditorium**

**12:25 - 13:55 h Oral Session 13: TED**

Chair(s): ()

- 12:25 - 12:35 VRDN-003, a Full Antagonist Antibody to IGF-1R for Thyroid Eye Disease (TED): Phase 1 Results Show Potential for Subcutaneous Administration  
*Mario Salvi (Italy)*
- 12:37 - 12:47 Response to Teprotumumab is Independent of Race, Ethnicity, and Age  
*George J. Kahaly (Germany)*
- 12:49 - 12:59 Teprotumumab Efficacy in Smokers and Non-Smokers: A Pooled Analysis from Clinical Trials in Patients with Acute TED  
*George J. Kahaly (Germany)*
- 13:01 - 13:11 Target-tissue immunophenotyping of patients with Thyroid Eye Disease before and after therapy with steroids, tocilizumab and rituximab.  
*Ilaria Muller (Italy)*
- 13:13 - 13:23 Efficacy of Teprotumumab on medical and surgical resistant DON  
*Anna Lucia Carretti (France)*
- 13:25 - 13:35 Prognostic Factors and Outcomes of Intravenous Glucocorticoid Pulse Therapy in Moderate-to-Severe Thyroid Eye Disease  
*Anna Giannakogeorgou (Germany)*
- 13:37 - 13:47 Long-term outcome of Graves' orbitopathy following treatment with sirolimus (rapamycin)  
*Simone Comi (Italy)*

**Amphitheatre**

**14:05 - 14:20 h Prize Ceremony and closure**

Chair(s): *Laura Fugazzola (Italy) and Kris Poppe (Belgium)*